Comparison of modified-release hydrocortisone capsules versus prednisolone in the treatment of congenital adrenal hyperplasia
Endocrine Connections · 27.06.2024 · 13 (8)
DOI: 10.1530/ec-24-0150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Connections, erschienen am 27.06.2024. Verfasst von Dafydd Aled Rees und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cardiff University, Cardiff, United Kingdom. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Prednisolone and prednisone are recommended treatment options for adults with congenital adrenal hyperplasia (CAH); however, there is no randomised comparison of prednis(ol)one with hydrocortisone.
Design
Six-month open-label randomised phase 3 study and interim analysis of a single-arm extension study was the design of the study.
Methods
The method of the study was hydrocortisone dose equivalent and 09:00-h 17-hydroxyprogesterone (17OHP) from 48 patients taking prednis(ol)one at baseline.
Results
At baseline, the median hydrocortisone dose equivalent was 30 mg/day and 17OHP was < 36 nmol/L (3× upper limit of normal) in 56% of patients. Patients were randomised to continue prednis(ol)one or switch to modified-release hydrocortisone capsule (MRHC) at the same hydrocortisone-equivalent dose. At 4 weeks, 94% on MRHC and 71% on prednis(ol)one had 17OHP < 36 nmol/L. At 18 months in the extension study of MRHC, the median MRHC dose was 20 mg/day and 82% had 17OHP < 36 nmol/L. The per cent of patients with 17OHP < 36 nmol/L on a hydrocortisone dose equivalent ≤ 25 mg/day was greater at 18 months in the extension study on MRHC than while on prednis(ol)one at baseline: 57% vs 27%, P = 0.04. In the randomised study, no patients had an adrenal crisis on MRHC and one on prednisolone. In the extension study (221 patient years), there were 12 adrenal crises in 5 patients (5.4/100 patient years).
Conclusion
MRHC reduces 17OHP at 09:00 h compared to prednis(ol)one and the dose of MRHC can be down-titrated over time in the majority of patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiff University, Cardiff, United Kingdom.
- National Institutes of Health Clinical Center and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, USA.
- MRC LMS, London, United Kingdom.
- Hospices Civils de Lyon - GHE - Endocrinologie, Bron, France.
- Karolinska Institute, Solna, Sweden.
- Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Dafydd Aled Rees, Anders Juul, Alessandro Prete, Nicole Reisch, Philippe A Touraine, Richard J Ross
Zitieren
APA
Rees, D. A., Merke, D. P., Arlt, W., Brac De La Perriere, A., Hirschberg, A. L., Juul, A., Newell-Price, J., Prete, A., Reisch, N., Stikkelbroeck, N. M., Touraine, P. A., Lewis, A., Porter, J., Coope, H., & Ross, R. J. (2024). Comparison of modified-release hydrocortisone capsules versus prednisolone in the treatment of congenital adrenal hyperplasia. Endocrine Connections, 13(8). https://doi.org/10.1530/ec-24-0150
Vancouver
Rees DA, Merke DP, Arlt W, Brac De La Perriere A, Hirschberg AL, Juul A, et al. Comparison of modified-release hydrocortisone capsules versus prednisolone in the treatment of congenital adrenal hyperplasia. Endocrine Connections. 2024;13(8). doi:10.1530/ec-24-0150
BibTeX
@article{Rees2024,
author = {Rees, Dafydd Aled and Merke, Deborah P and Arlt, Wiebke and Brac De La Perriere, Aude and Hirschberg, Angelica Linden and Juul, Anders and Newell-Price, John and Prete, Alessandro and Reisch, Nicole and Stikkelbroeck, Nike M and Touraine, Philippe A and Lewis, Alex and Porter, John and Coope, Helen and Ross, Richard J},
title = {Comparison of modified-release hydrocortisone capsules versus prednisolone in the treatment of congenital adrenal hyperplasia},
journal = {Endocrine Connections},
year = {2024},
volume = {13},
number = {8},
doi = {10.1530/ec-24-0150}
}
EUVIMED